For instance, treatment of tumor-bearing mice with VEGFR2-blocking antibodies, sunitinib (Sutent, Pfizer, a multi-targeted receptor tyrosine kinase inhibitor) or genetic deletion of VEGFA shows anti-tumor effects but also triggers local invasiveness and metastasis [22]. This evidence concerns the gene KDR and neoplasm.